CAR designs for solid tumors: overcoming hurdles and paving the way for effective immunotherapy

Yuanbin Cui; Mintao Luo; Chuanyuan Gu; Yuxian He; Yao Yao; Peng Li

doi:10.52601/bpr.2023.230020

Volume 9 Issue 5

Oct. 2023

Turn off MathJax

Article Contents

Article Navigation > Biophysics Reports > 2023 > 9(5): 279-297

Yuanbin Cui, Mintao Luo, Chuanyuan Gu, Yuxian He, Yao Yao, Peng Li. CAR designs for solid tumors: overcoming hurdles and paving the way for effective immunotherapy. Biophysics Reports, 2023, 9(5): 279-297. doi: 10.52601/bpr.2023.230020

Citation:

Yuanbin Cui, Mintao Luo, Chuanyuan Gu, Yuxian He, Yao Yao, Peng Li. CAR designs for solid tumors: overcoming hurdles and paving the way for effective immunotherapy. Biophysics Reports, 2023, 9(5): 279-297. doi: 10.52601/bpr.2023.230020

Citation:

PDF (2511 KB)

CAR designs for solid tumors: overcoming hurdles and paving the way for effective immunotherapy

doi: 10.52601/bpr.2023.230020

1.
China-New Zealand Joint Laboratory of Biomedicine and Health, State Key Laboratory of Respiratory Disease, CAS Key Laboratory of Regenerative Biology, Guangdong Provincial Key Laboratory of Stem Cell and Regenerative Medicine, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou 510530, China
2.
University of California San Diego, La Jolla, CA 92093-0021, USA

More Information

Corresponding author: li_peng@gibh.ac.cn (P. Li)
Received Date: 17 October 2023
Accepted Date: 28 November 2023

Available Online: 26 February 2024

Publish Date: 01 October 2023

Abstract

Abstract

Chimeric antigen receptor T cell (CAR-T) therapy has revolutionized immunotherapy by modifying patients' immune cells genetically. By expressing CARs, these modified cells can specifically identify and eliminate tumor cells. The success of CAR-T therapy in hematological malignancies, such as leukemia and lymphoma, has been remarkable. Numerous studies have reported improved patient outcomes and increased survival rates. However, the application of CAR-T therapy in treating solid tumors faces significant challenges. Solid tumors possess complex microenvironments containing stromal cells, extracellular matrix components, and blood vessels. These factors can impede the infiltration and persistence of CAR-T cells within the tumor. Additionally, the lack of target antigens exclusively expressed on tumor cells raises concerns about off-target effects and potential toxicity. This review aims to discuss advancements achieved by CAR-T therapy in solid tumors and the clinical outcomes in the realm of solid tumors.
- Chimeric antigen receptor T cell,
- Solid tumor,
- Immunotherapy

Yuanbin Cui, Mintao Luo, Chunyuan Gu, Yuxian He, Yao Yao, and Peng Li declare that they have no conflict of interest.
This article does not contain any studies with human or animal subjects performed by any of the authors.

FullText(HTML)

References(96)

References

Adachi K, Kano Y, Nagai T, Okuyama N, Sakoda Y, Tamada K (2018) IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor. Nat Biotechnol 36(4): 346−351 doi: 10.1038/nbt.4086

Adusumilli PS, Zauderer MG, Riviere I, Solomon SB, Rusch VW, O'Cearbhaill RE, Zhu A, Cheema W, Chintala NK, Halton E, Pineda J, Perez-Johnston R, Tan KS, Daly B, Araujo Filho JA, Ngai D, McGee E, Vincent A, Diamonte C, Sauter JL, Modi S, Sikder D, Senechal B, Wang X, Travis WD, Gonen M, Rudin CM, Brentjens RJ, Jones DR, Sadelain M (2021) A phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the anti-PD-1 agent pembrolizumab. Cancer Discov 11(11): 2748−2763 doi: 10.1158/2159-8290.CD-21-0407

Agliardi G, Liuzzi AR, Hotblack A, De Feo D, Nunez N, Stowe CL, Friebel E, Nannini F, Rindlisbacher L, Roberts TA, Ramasawmy R, Williams IP, Siow BM, Lythgoe MF, Kalber TL, Quezada SA, Pule MA, Tugues S, Straathof K, Becher B (2021) Intratumoral IL-12 delivery empowers CAR-T cell immunotherapy in a pre-clinical model of glioblastoma. Nat Commun 12(1): 444. https://doi.org/10.1038/s41467-020-20599-x

Albert S, Arndt C, Feldmann A, Bergmann R, Bachmann D, Koristka S, Ludwig F, Ziller-Walter P, Kegler A, Gartner S, Schmitz M, Ehninger A, Cartellieri M, Ehninger G, Pietzsch HJ, Pietzsch J, Steinbach J, Bachmann M (2017) A novel nanobody-based target module for retargeting of T lymphocytes to EGFR-expressing cancer cells via the modular UniCAR platform. Oncoimmunology 6(4): e1287246. https://doi.org/10.1080/2162402X.2017.1287246

Alfaro C, Sanmamed MF, Rodriguez-Ruiz ME, Teijeira A, Onate C, Gonzalez A, Ponz M, Schalper KA, Perez-Gracia JL, Melero I (2017) Interleukin-8 in cancer pathogenesis, treatment and follow-up. Cancer Treat Rev 60: 24−31 doi: 10.1016/j.ctrv.2017.08.004

Atar D, Mast AS, Scheuermann S, Ruoff L, Seitz CM, Schlegel P (2022) Adapter CAR T cell therapy for the treatment of B-lineage lymphomas. Biomedicines 10(10): 2420. https://doi.org/10.3390/biomedicines10102420

Batra SA, Rathi P, Guo L, Courtney AN, Fleurence J, Balzeau J, Shaik RS, Nguyen TP, Wu MF, Bulsara S, Mamonkin M, Metelitsa LS, Heczey A (2020) Glypican-3-specific CAR T cells coexpressing IL15 and IL21 have superior expansion and antitumor activity against hepatocellular carcinoma. Cancer Immunol Res 8(3): 309−320 doi: 10.1158/2326-6066.CIR-19-0293

Beatty GL, O'Hara MH, Lacey SF, Torigian DA, Nazimuddin F, Chen F, Kulikovskaya IM, Soulen MC, McGarvey M, Nelson AM, Gladney WL, Levine BL, Melenhorst JJ, Plesa G, June CH (2018) Activity of mesothelin-specific chimeric antigen receptor T cells against pancreatic carcinoma metastases in a phase 1 trial. Gastroenterology 155(1): 29−32 doi: 10.1053/j.gastro.2018.03.029

Brog RA, Ferry SL, Schiebout CT, Messier CM, Cook WJ, Abdullah L, Zou J, Kumar P, Sentman CL, Frost HR, Huang YH (2022) Superkine IL-2 and IL-33 armored CAR T cells reshape the tumor microenvironment and reduce growth of multiple solid tumors. Cancer Immunol Res 10(8): 962−977 doi: 10.1158/2326-6066.CIR-21-0536

Bueno C, Velasco-Hernandez T, Gutierrez-Aguera F, Zanetti SR, Baroni ML, Sanchez-Martinez D, Molina O, Closa A, Agraz-Doblas A, Marin P, Eyras E, Varela I, Menendez P (2019) CD133-directed CAR T-cells for MLL leukemia: on-target, off-tumor myeloablative toxicity. Leukemia 33(8): 2090−2125 doi: 10.1038/s41375-019-0418-8

Bughda R, Dimou P, D'Souza RR, Klampatsa A (2021) Fibroblast activation protein (FAP)-targeted CAR-T cells: launching an attack on tumor stroma. Immunotargets Ther 10: 313−323 doi: 10.2147/ITT.S291767

Byrd TT, Fousek K, Pignata A, Szot C, Samaha H, Seaman S, Dobrolecki L, Salsman VS, Oo HZ, Bielamowicz K, Landi D, Rainusso N, Hicks J, Powell S, Baker ML, Wels WS, Koch J, Sorensen PH, Deneen B, Ellis MJ, Lewis MT, Hegde M, Fletcher BS, St Croix B, Ahmed N (2018) TEM8/ANTXR1-specific CAR T cells as a targeted therapy for triple-negative breast cancer. Cancer Res 78(2): 489−500 doi: 10.1158/0008-5472.CAN-16-1911

Caforio M, Sorino C, Caruana I, Weber G, Camera A, Cifaldi L, De Angelis B, Del Bufalo F, Vitale A, Goffredo BM, De Vito R, Fruci D, Quintarelli C, Fanciulli M, Locatelli F, Folgiero V (2021) GD2 redirected CAR T and activated NK-cell-mediated secretion of IFNgamma overcomes MYCN-dependent IDO1 inhibition, contributing to neuroblastoma cell immune escape. J Immunother Cancer 9(3): e001502. https://doi.org/10.1136/jitc-2020-001502

Cao W, Xing H, Li Y, Tian W, Song Y, Jiang Z, Yu J (2022) Claudin18.2 is a novel molecular biomarker for tumor-targeted immunotherapy. Biomark Res 10(1): 38. doi: 10.1186/s40364-022-00385-1

Cao Y, Rodgers DT, Du J, Ahmad I, Hampton EN, Ma JS, Mazagova M, Choi SH, Yun HY, Xiao H, Yang P, Luo X, Lim RK, Pugh HM, Wang F, Kazane SA, Wright TM, Kim CH, Schultz PG, Young TS (2016) Design of switchable chimeric antigen receptor T cells targeting breast cancer. Angew Chem Int Ed Engl 55(26): 7520−7524 doi: 10.1002/anie.201601902

Carnevale J, Shifrut E, Kale N, Nyberg WA, Blaeschke F, Chen YY, Li Z, Bapat SP, Diolaiti ME, O'Leary P, Vedova S, Belk J, Daniel B, Roth TL, Bachl S, Anido AA, Prinzing B, Ibanez-Vega J, Lange S, Haydar D, Luetke-Eversloh M, Born-Bony M, Hegde B, Kogan S, Feuchtinger T, Okada H, Satpathy AT, Shannon K, Gottschalk S, Eyquem J, Krenciute G, Ashworth A, Marson A (2022) RASA2 ablation in T cells boosts antigen sensitivity and long-term function. Nature 609(7925): 174−182 doi: 10.1038/s41586-022-05126-w

Caruana I, Savoldo B, Hoyos V, Weber G, Liu H, Kim ES, Ittmann MM, Marchetti D, Dotti G (2015) Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes. Nat Med 21(5): 524−529 doi: 10.1038/nm.3833

Castelletti L, Yeo D, van Zandwijk N, Rasko JEJ (2021) Anti-Mesothelin CAR T cell therapy for malignant mesothelioma. Biomark Res 9(1): 11. https://doi.org/10.1186/s40364-021-00264-1

Cherkassky L, Morello A, Villena-Vargas J, Feng Y, Dimitrov DS, Jones DR, Sadelain M, Adusumilli PS (2016) Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. J Clin Invest 126(8): 3130−3144 doi: 10.1172/JCI83092

Cho JH, Collins JJ, Wong WW (2018) Universal chimeric antigen receptors for multiplexed and logical control of T cell responses. Cell 173(6): 1426-1438 e1411

Choi BD, Yu X, Castano AP, Bouffard AA, Schmidts A, Larson RC, Bailey SR, Boroughs AC, Frigault MJ, Leick MB, Scarfo I, Cetrulo CL, Demehri S, Nahed BV, Cahill DP, Wakimoto H, Curry WT, Carter BS, Maus MV (2019) CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity. Nat Biotechnol 37(9): 1049−1058 doi: 10.1038/s41587-019-0192-1

Craddock JA, Lu A, Bear A, Pule M, Brenner MK, Rooney CM, Foster AE (2010) Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b. J Immunother 33(8): 780−788 doi: 10.1097/CJI.0b013e3181ee6675

Cui Y, Yuan T, Wang Y, Zheng D, Qin L, Li S, Jiang Z, Lin S, Guo W, Wang Z, Liang Z, Li Y, Yao Y, Liu X, Tang Q, Tu HY, Zhang XC, Tang Z, Wong N, Zhang Z, Qin D, Thiery JP, Xu K, Li P (2023) T lymphocytes expressing the switchable chimeric Fc receptor CD64 exhibit augmented persistence and antitumor activity. Cell Rep 42(7): 112797. https://doi.org/10.1016/j.celrep.2023.112797

D'Aloia MM, Caratelli S, Palumbo C, Battella S, Arriga R, Lauro D, Palmieri G, Sconocchia G, Alimandi M (2016) T lymphocytes engineered to express a CD16-chimeric antigen receptor redirect T-cell immune responses against immunoglobulin G-opsonized target cells. Cytotherapy 18(2): 278−290 doi: 10.1016/j.jcyt.2015.10.014

Dai H, Tong C, Shi D, Chen M, Guo Y, Chen D, Han X, Wang H, Wang Y, Shen P (2020) Efficacy and biomarker analysis of CD133-directed CAR T cells in advanced hepatocellular carcinoma: a single-arm, open-label, phase II trial. Oncoimmunology 9(1): 1846926. https://doi.org/10.1080/2162402X.2020.1846926

Del Bufalo F, De Angelis B, Caruana I, Del Baldo G, De Ioris MA, Serra A, Mastronuzzi A, Cefalo MG, Pagliara D, Amicucci M, Li Pira G, Leone G, Bertaina V, Sinibaldi M, Di Cecca S, Guercio M, Abbaszadeh Z, Iaffaldano L, Gunetti M, Iacovelli S, Bugianesi R, Macchia S, Algeri M, Merli P, Galaverna F, Abbas R, Garganese MC, Villani MF, Colafati GS, Bonetti F, Rabusin M, Perruccio K, Folsi V, Quintarelli C, Locatelli F, Precision Medicine Team IOPBG (2023) GD2-CART01 for relapsed or refractory high-risk neuroblastoma. N Engl J Med 388(14): 1284−1295 doi: 10.1056/NEJMoa2210859

Di Stasi A, De Angelis B, Rooney CM, Zhang L, Mahendravada A, Foster AE, Heslop HE, Brenner MK, Dotti G, Savoldo B (2009) T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. Blood 113(25): 6392−6402 doi: 10.1182/blood-2009-03-209650

Duan D, Wang K, Wei C, Feng D, Liu Y, He Q, Xu X, Wang C, Zhao S, Lv L, Long J, Lin D, Zhao A, Fang B, Jiang J, Tang S, Gao J (2021) The BCMA-targeted fourth-generation CAR-T cells secreting IL-7 and CCL19 for therapy of refractory/recurrent multiple myeloma. Front Immunol 12: 609421. https://doi.org/10.3389/fimmu.2021.609421

Duan Y, Chen J, Meng X, Liu L, Shang K, Wu X, Wang Y, Huang Z, Liu H, Huang Y, Zhou C, Gao X, Wang Y, Sun J (2023) Balancing activation and co-stimulation of CAR tunes signaling dynamics and enhances therapeutic potency. Mol Ther 31(1): 35−47 doi: 10.1016/j.ymthe.2022.08.018

Feucht J, Sun J, Eyquem J, Ho YJ, Zhao Z, Leibold J, Dobrin A, Cabriolu A, Hamieh M, Sadelain M (2019) Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency. Nat Med 25(1): 82−88 doi: 10.1038/s41591-018-0290-5

Forsberg EMV, Lindberg MF, Jespersen H, Alsen S, Bagge RO, Donia M, Svane IM, Nilsson O, Ny L, Nilsson LM, Nilsson JA (2019) HER2 CAR-T cells eradicate uveal melanoma and T-cell therapy-resistant human melanoma in IL2 transgenic NOD/SCID IL2 receptor knockout mice. Cancer Res 79(5): 899−904 doi: 10.1158/0008-5472.CAN-18-3158

Gargett T, Ebert LM, Truong NTH, Kollis PM, Sedivakova K, Yu W, Yeo ECF, Wittwer NL, Gliddon BL, Tea MN, Ormsby R, Poonnoose S, Nowicki J, Vittorio O, Ziegler DS, Pitson SM, Brown MP (2022) GD2-targeting CAR-T cells enhanced by transgenic IL-15 expression are an effective and clinically feasible therapy for glioblastoma. J Immunother Cancer 10(9): e005187. https://doi.org/10.1136/jitc-2022-005187

Good CR, Aznar MA, Kuramitsu S, Samareh P, Agarwal S, Donahue G, Ishiyama K, Wellhausen N, Rennels AK, Ma Y, Tian L, Guedan S, Alexander KA, Zhang Z, Rommel PC, Singh N, Glastad KM, Richardson MW, Watanabe K, Tanyi JL, O'Hara MH, Ruella M, Lacey SF, Moon EK, Schuster SJ, Albelda SM, Lanier LL, Young RM, Berger SL, June CH (2021) An NK-like CAR T cell transition in CAR T cell dysfunction. Cell 184(25): 6081-6100 e6026

Hawkins ER, D'Souza RR, Klampatsa A (2021) Armored CAR T-cells: the next chapter in T-cell cancer immunotherapy. Biologics 15: 95−105

Hegde M, Mukherjee M, Grada Z, Pignata A, Landi D, Navai SA, Wakefield A, Fousek K, Bielamowicz K, Chow KK, Brawley VS, Byrd TT, Krebs S, Gottschalk S, Wels WS, Baker ML, Dotti G, Mamonkin M, Brenner MK, Orange JS, Ahmed N (2016) Tandem CAR T cells targeting HER2 and IL13Ralpha2 mitigate tumor antigen escape. J Clin Invest 126(8): 3036−3052 doi: 10.1172/JCI83416

Hu X, Chen R, Wei Q, Xu X (2022) The landscape of alpha fetoprotein in hepatocellular carcinoma: where are we? Int J Biol Sci 18(2): 536-551

Jiang H, Shi Z, Wang P, Wang C, Yang L, Du G, Zhang H, Shi B, Jia J, Li Q, Wang H, Li Z (2019) Claudin18.2-specific chimeric antigen receptor engineered T cells for the treatment of gastric cancer. J Natl Cancer Inst 111(4): 409-418

Jiang Z, Liao R, Lv J, Li S, Zheng D, Qin L, Wu D, Chen S, Long Y, Wu Q, Wang S, Lin S, Huang X, Tang Z, Shi P, Zhou H, Liu Q, Zhao R, Li Y, Jie Y, Wei W, Lai P, Du X, Cui S, Weinkove R, Liu P, Pei D, Yao Y, Li P (2021) IL-6 trans-signaling promotes the expansion and anti-tumor activity of CAR T cells. Leukemia 35(5): 1380−1391 doi: 10.1038/s41375-020-01085-1

Jin L, Tao H, Karachi A, Long Y, Hou AY, Na M, Dyson KA, Grippin AJ, Deleyrolle LP, Zhang W, Rajon DA, Wang QJ, Yang JC, Kresak JL, Sayour EJ, Rahman M, Bova FJ, Lin Z, Mitchell DA, Huang J (2019) CXCR1- or CXCR2-modified CAR T cells co-opt IL-8 for maximal antitumor efficacy in solid tumors. Nat Commun 10(1): 4016. https://doi.org/10.1038/s41467-019-11869-4

Kakarla S, Chow KK, Mata M, Shaffer DR, Song XT, Wu MF, Liu H, Wang LL, Rowley DR, Pfizenmaier K, Gottschalk S (2013) Antitumor effects of chimeric receptor engineered human T cells directed to tumor stroma. Mol Ther 21(8): 1611−1620 doi: 10.1038/mt.2013.110

Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, June CH (2011) T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 3(95): 95ra73. https://doi.org/10.1126/scitranslmed.3002842

Kloss CC, Lee J, Zhang A, Chen F, Melenhorst JJ, Lacey SF, Maus MV, Fraietta JA, Zhao Y, June CH (2018) Dominant-negative TGF-beta receptor enhances PSMA-targeted human CAR T cell proliferation and augments prostate cancer eradication. Mol Ther 26(7): 1855−1866 doi: 10.1016/j.ymthe.2018.05.003

Labanieh L, Majzner RG, Klysz D, Sotillo E, Fisher CJ, Vilches-Moure JG, Pacheco KZB, Malipatlolla M, Xu P, Hui JH, Murty T, Theruvath J, Mehta N, Yamada-Hunter SA, Weber EW, Heitzeneder S, Parker KR, Satpathy AT, Chang HY, Lin MZ, Cochran JR, Mackall CL (2022) Enhanced safety and efficacy of protease-regulated CAR-T cell receptors. Cell 185(10): 1745‒1763 e1722

Lai Y, Weng J, Wei X, Qin L, Lai P, Zhao R, Jiang Z, Li B, Lin S, Wang S, Wu Q, Tang Z, Liu P, Pei D, Yao Y, Du X, Li P (2018) Toll-like receptor 2 costimulation potentiates the antitumor efficacy of CAR T Cells. Leukemia 32(3): 801−808 doi: 10.1038/leu.2017.249

Lanitis E, Rota G, Kosti P, Ronet C, Spill A, Seijo B, Romero P, Dangaj D, Coukos G, Irving M (2021) Optimized gene engineering of murine CAR-T cells reveals the beneficial effects of IL-15 coexpression. J Exp Med 218(2): e20192203. https://doi.org/10.1084/jem.20192203

Larson SM, Walthers CM, Ji B, Ghafouri SN, Naparstek J, Trent J, Chen JM, Roshandell M, Harris C, Khericha M, Schweppe T, Berent-Maoz B, Gosliner SB, Almaktari A, Ceja MA, Allen-Auerbach MS, Said J, Nawaly K, Mead M, de Vos S, Young PA, Oliai C, Schiller GJ, Timmerman JM, Ribas A, Chen YY (2023) CD19/CD20 bispecific chimeric antigen receptor (CAR) in naive/memory T cells for the treatment of relapsed or refractory non-Hodgkin lymphoma. Cancer Discov 13(3): 580−597 doi: 10.1158/2159-8290.CD-22-0964

Lee YH, Lee HJ, Kim HC, Lee Y, Nam SK, Hupperetz C, Ma JSY, Wang X, Singer O, Kim WS, Kim SJ, Koh Y, Jung I, Kim CH (2022) PD-1 and TIGIT downregulation distinctly affect the effector and early memory phenotypes of CD19-targeting CAR T cells. Mol Ther 30(2): 579−592 doi: 10.1016/j.ymthe.2021.10.004

Liu G, Rui W, Zheng H, Huang D, Yu F, Zhang Y, Dong J, Zhao X, Lin X (2020) CXCR2-modified CAR-T cells have enhanced trafficking ability that improves treatment of hepatocellular carcinoma. Eur J Immunol 50(5): 712−724 doi: 10.1002/eji.201948457

Liu H, Xu Y, Xiang J, Long L, Green S, Yang Z, Zimdahl B, Lu J, Cheng N, Horan LH, Liu B, Yan S, Wang P, Diaz J, Jin L, Nakano Y, Morales JF, Zhang P, Liu LX, Staley BK, Priceman SJ, Brown CE, Forman SJ, Chan VW, Liu C (2017) Targeting alpha-fetoprotein (AFP)-MHC complex with CAR T-cell therapy for liver cancer. Clin Cancer Res 23(2): 478−488 doi: 10.1158/1078-0432.CCR-16-1203

Lohmueller JJ, Ham JD, Kvorjak M, Finn OJ (2017) mSA2 affinity-enhanced biotin-binding CAR T cells for universal tumor targeting. Oncoimmunology 7(1): e1368604. https://doi.org/10.1080/2162402X.2017.1368604

Luo H, Su J, Sun R, Sun Y, Wang Y, Dong Y, Shi B, Jiang H, Li Z (2020) Coexpression of IL7 and CCL21 increases efficacy of CAR-T cells in solid tumors without requiring preconditioned lymphodepletion. Clin Cancer Res 26(20): 5494−5505 doi: 10.1158/1078-0432.CCR-20-0777

Lv J, Qin L, Zhao R, Wu D, Wu Z, Zheng D, Li S, Luo M, Wu Q, Long Y, Tang Z, Tang YL, Luo X, Yao Y, Yang LH, Li P (2023) Disruption of CISH promotes the antitumor activity of human T cells and decreases PD-1 expression levels. Mol Ther Oncolytics 28: 46−58 doi: 10.1016/j.omto.2022.12.003

Lv J, Zhao R, Wu D, Zheng D, Wu Z, Shi J, Wei X, Wu Q, Long Y, Lin S, Wang S, Wang Z, Li Y, Chen Y, He Q, Chen S, Yao H, Liu Z, Tang Z, Yao Y, Pei D, Liu P, Zhang X, Zhang Z, Cui S, Chen R, Li P (2019) Mesothelin is a target of chimeric antigen receptor T cells for treating gastric cancer. J Hematol Oncol 12(1): 18. https://doi.org/10.1186/s13045-019-0704-y

Ma Q, He X, Zhang B, Guo F, Ou X, Yang Q, Shu P, Chen Y, Li K, Gao G, Zhu Y, Qin D, Tang J, Li X, Jing M, Zhao J, Mo Z, Liu N, Zeng Y, Zhou K, Feng M, Liao W, Lei W, Li Q, Li D, Wang Y (2022) A PD-L1-targeting chimeric switch receptor enhances efficacy of CAR-T cell for pleural and peritoneal metastasis. Signal Transduct Target Ther 7(1): 380. https://doi.org/10.1038/s41392-022-01198-2

Ma X, Shou P, Smith C, Chen Y, Du H, Sun C, Porterfield Kren N, Michaud D, Ahn S, Vincent B, Savoldo B, Pylayeva-Gupta Y, Zhang S, Dotti G, Xu Y (2020) Interleukin-23 engineering improves CAR T cell function in solid tumors. Nat Biotechnol 38(4): 448−459 doi: 10.1038/s41587-019-0398-2

Majzner RG, Ramakrishna S, Yeom KW, Patel S, Chinnasamy H, Schultz LM, Richards RM, Jiang L, Barsan V, Mancusi R, Geraghty AC, Good Z, Mochizuki AY, Gillespie SM, Toland AMS, Mahdi J, Reschke A, Nie EH, Chau IJ, Rotiroti MC, Mount CW, Baggott C, Mavroukakis S, Egeler E, Moon J, Erickson C, Green S, Kunicki M, Fujimoto M, Ehlinger Z, Reynolds W, Kurra S, Warren KE, Prabhu S, Vogel H, Rasmussen L, Cornell TT, Partap S, Fisher PG, Campen CJ, Filbin MG, Grant G, Sahaf B, Davis KL, Feldman SA, Mackall CL, Monje M (2022) GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas. Nature 603(7903): 934−941 doi: 10.1038/s41586-022-04489-4

Mao Y, Fan W, Hu H, Zhang L, Michel J, Wu Y, Wang J, Jia L, Tang X, Xu L, Chen Y, Zhu J, Feng Z, Xu L, Yin R, Tang Q (2019) MAGE-A1 in lung adenocarcinoma as a promising target of chimeric antigen receptor T cells. J Hematol Oncol 12(1): 106. https://doi.org/10.1186/s13045-019-0793-7

McCue AC, Yao Z, Kuhlman B (2022) Advances in modular control of CAR-T therapy with adapter-mediated CARs. Adv Drug Deliv Rev 187: 114358. https://doi.org/10.1016/j.addr.2022.114358

Moghimi B, Muthugounder S, Jambon S, Tibbetts R, Hung L, Bassiri H, Hogarty MD, Barrett DM, Shimada H, Asgharzadeh S (2021) Preclinical assessment of the efficacy and specificity of GD2-B7H3 SynNotch CAR-T in metastatic neuroblastoma. Nat Commun 12(1): 511. https://doi.org/10.1038/s41467-020-20785-x

Moon EK, Carpenito C, Sun J, Wang LC, Kapoor V, Predina J, Powell DJ, Jr., Riley JL, June CH, Albelda SM (2011) Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor. Clin Cancer Res 17(14): 4719−4730 doi: 10.1158/1078-0432.CCR-11-0351

Mount CW, Majzner RG, Sundaresh S, Arnold EP, Kadapakkam M, Haile S, Labanieh L, Hulleman E, Woo PJ, Rietberg SP, Vogel H, Monje M, Mackall CL (2018) Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M(+) diffuse midline gliomas. Nat Med 24(5): 572−579 doi: 10.1038/s41591-018-0006-x

Narayan V, Barber-Rotenberg JS, Jung IY, Lacey SF, Rech AJ, Davis MM, Hwang WT, Lal P, Carpenter EL, Maude SL, Plesa G, Vapiwala N, Chew A, Moniak M, Sebro RA, Farwell MD, Marshall A, Gilmore J, Lledo L, Dengel K, Church SE, Hether TD, Xu J, Gohil M, Buckingham TH, Yee SS, Gonzalez VE, Kulikovskaya I, Chen F, Tian L, Tien K, Gladney W, Nobles CL, Raymond HE, Prostate Cancer Cellular Therapy Program I, Hexner EO, Siegel DL, Bushman FD, June CH, Fraietta JA, Haas NB (2022) PSMA-targeting TGFbeta-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial. Nat Med 28(4): 724−734 doi: 10.1038/s41591-022-01726-1

Niu W, Liu J, Huang J, Chen B, He Q, Wang AL, Lu Q, Chen Y, Yun Q, Wang J, Li C, Huang Y, Lai Z, Fan Z, Wu XJ, Zhang H (2019) Unusual 4H-phase twinned noble metal nanokites. Nat Commun 10(1): 2881. https://doi.org/10.1038/s41467-019-10764-2

Noh KE, Lee JH, Choi SY, Jung NC, Nam JH, Oh JS, Song JY, Seo HG, Wang Y, Lee HS, Lim DS (2021) TGF-beta/IL-7 chimeric switch receptor-expressing CAR-T cells inhibit recurrence of CD19-positive B cell lymphoma. Int J Mol Sci 22(16): 8706. https://doi.org/10.3390/ijms22168706

Pang N, Shi J, Qin L, Chen A, Tang Y, Yang H, Huang Y, Wu Q, Li X, He B, Li T, Liang B, Zhang J, Cao B, Liu M, Feng Y, Ye X, Chen X, Wang L, Tian Y, Li H, Li J, Hu H, He J, Hu Y, Zhi C, Tang Z, Gong Y, Xu F, Xu L, Fan W, Zhao M, Chen D, Lian H, Yang L, Li P, Zhang Z (2021) IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin. J Hematol Oncol 14(1): 118. https://doi.org/10.1186/s13045-021-01128-9

Qi C, Gong J, Li J, Liu D, Qin Y, Ge S, Zhang M, Peng Z, Zhou J, Cao Y, Zhang X, Lu Z, Lu M, Yuan J, Wang Z, Wang Y, Peng X, Gao H, Liu Z, Wang H, Yuan D, Xiao J, Ma H, Wang W, Li Z, Shen L (2022) Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results. Nat Med 28(6): 1189‒1198

Qin L, Cui Y, Yuan T, Chen D, Zhao R, Li S, Jiang Z, Wu Q, Long Y, Wang S, Tang Z, Pan H, Li X, Wei W, Yang J, Luo X, Zhang Z, Tang Q, Liu P, Weinkove R, Yao Y, Qin D, Thiery JP, Li P (2022) Co-expression of a PD-L1-specific chimeric switch receptor augments the efficacy and persistence of CAR T cells via the CD70-CD27 axis. Nat Commun 13(1): 6051. https://doi.org/10.1038/s41467-022-33793-w

Rafiq S, Yeku OO, Jackson HJ, Purdon TJ, van Leeuwen DG, Drakes DJ, Song M, Miele MM, Li Z, Wang P, Yan S, Xiang J, Ma X, Seshan VE, Hendrickson RC, Liu C, Brentjens RJ (2018) Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo. Nat Biotechnol 36(9): 847−856 doi: 10.1038/nbt.4195

Roberts EW, Deonarine A, Jones JO, Denton AE, Feig C, Lyons SK, Espeli M, Kraman M, McKenna B, Wells RJ, Zhao Q, Caballero OL, Larder R, Coll AP, O'Rahilly S, Brindle KM, Teichmann SA, Tuveson DA, Fearon DT (2013) Depletion of stromal cells expressing fibroblast activation protein-alpha from skeletal muscle and bone marrow results in cachexia and anemia. J Exp Med 210(6): 1137−1151 doi: 10.1084/jem.20122344

Schoutrop E, El-Serafi I, Poiret T, Zhao Y, Gultekin O, He R, Moyano-Galceran L, Carlson JW, Lehti K, Hassan M, Magalhaes I, Mattsson J (2021) Mesothelin-specific CAR T cells target ovarian cancer. Cancer Res 81(11): 3022−3035 doi: 10.1158/0008-5472.CAN-20-2701

Schoutrop E, Poiret T, El-Serafi I, Zhao Y, He R, Moter A, Henriksson J, Hassan M, Magalhaes I, Mattsson J (2023) Tuned activation of MSLN-CAR T cells induces superior antitumor responses in ovarian cancer models. J Immunother Cancer 11(2): e005691. https://doi.org/10.1136/jitc-2022-005691

Schuberth PC, Hagedorn C, Jensen SM, Gulati P, van den Broek M, Mischo A, Soltermann A, Jungel A, Marroquin Belaunzaran O, Stahel R, Renner C, Petrausch U (2013) Treatment of malignant pleural mesothelioma by fibroblast activation protein-specific re-directed T cells. J Transl Med 11: 187. https://doi.org/10.1186/1479-5876-11-187

Shah NN, Johnson BD, Schneider D, Zhu F, Szabo A, Keever-Taylor CA, Krueger W, Worden AA, Kadan MJ, Yim S, Cunningham A, Hamadani M, Fenske TS, Dropulic B, Orentas R, Hari P (2020) Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial. Nat Med 26(10): 1569−1575 doi: 10.1038/s41591-020-1081-3

Song EZ, Milone MC (2021) Pharmacology of chimeric antigen receptor-modified T cells. Annu Rev Pharmacol Toxicol 61: 805−829 doi: 10.1146/annurev-pharmtox-031720-102211

Sotoudeh M, Shirvani SI, Merat S, Ahmadbeigi N, Naderi M (2019) MSLN (Mesothelin), ANTXR1 (TEM8), and MUC3A are the potent antigenic targets for CAR T cell therapy of gastric adenocarcinoma. J Cell Biochem 120(4): 5010−5017 doi: 10.1002/jcb.27776

Textor A, Grunewald L, Anders K, Klaus A, Schwiebert S, Winkler A, Stecklum M, Rolff J, Henssen AG, Hopken UE, Eggert A, Schulte JH, Jensen MC, Blankenstein T, Kunkele A (2021) CD28 co-stimulus achieves superior CAR T cell effector function against solid tumors than 4-1BB co-stimulus. Cancers (Basel) 13(5): 1050. https://doi.org/10.3390/cancers13051050

Tong C, Zhang Y, Liu Y, Ji X, Zhang W, Guo Y, Han X, Ti D, Dai H, Wang C, Yang Q, Liu W, Wang Y, Wu Z, Han W (2020) Optimized tandem CD19/CD20 CAR-engineered T cells in refractory/relapsed B-cell lymphoma. Blood 136(14): 1632−1644

Tran E, Chinnasamy D, Yu Z, Morgan RA, Lee CC, Restifo NP, Rosenberg SA (2013) Immune targeting of fibroblast activation protein triggers recognition of multipotent bone marrow stromal cells and cachexia. J Exp Med 210(6): 1125−1135 doi: 10.1084/jem.20130110

Urbanska K, Lanitis E, Poussin M, Lynn RC, Gavin BP, Kelderman S, Yu J, Scholler N, Powell DJ, Jr. (2012) A universal strategy for adoptive immunotherapy of cancer through use of a novel T-cell antigen receptor. Cancer Res 72(7): 1844−1852 doi: 10.1158/0008-5472.CAN-11-3890

Vitanza NA, Johnson AJ, Wilson AL, Brown C, Yokoyama JK, Kunkele A, Chang CA, Rawlings-Rhea S, Huang W, Seidel K, Albert CM, Pinto N, Gust J, Finn LS, Ojemann JG, Wright J, Orentas RJ, Baldwin M, Gardner RA, Jensen MC, Park JR (2021) Locoregional infusion of HER2-specific CAR T cells in children and young adults with recurrent or refractory CNS tumors: an interim analysis. Nat Med 27(9): 1544−1552 doi: 10.1038/s41591-021-01404-8

Vora P, Venugopal C, Salim SK, Tatari N, Bakhshinyan D, Singh M, Seyfrid M, Upreti D, Rentas S, Wong N, Williams R, Qazi MA, Chokshi C, Ding A, Subapanditha M, Savage N, Mahendram S, Ford E, Adile AA, McKenna D, McFarlane N, Huynh V, Wylie RG, Pan J, Bramson J, Hope K, Moffat J, Singh S (2020) The rational development of CD133-targeting immunotherapies for glioblastoma. Cell Stem Cell 26(6): 832‒844 e836

Wang LC, Lo A, Scholler J, Sun J, Majumdar RS, Kapoor V, Antzis M, Cotner CE, Johnson LA, Durham AC, Solomides CC, June CH, Pure E, Albelda SM (2014) Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity. Cancer Immunol Res 2(2): 154−166 doi: 10.1158/2326-6066.CIR-13-0027

Wang Y, Zhao Y, Li M, Hou H, Jian Z, Li W, Li P, Ma F, Liu M, Liu H, Xue H (2023) Conversion of primary liver cancer after targeted therapy for liver cancer combined with AFP-targeted CAR T-cell therapy: a case report. Front Immunol 14: 1180001. https://doi.org/10.3389/fimmu.2023.1180001

Wang Z, Li N, Feng K, Chen M, Zhang Y, Liu Y, Yang Q, Nie J, Tang N, Zhang X, Cheng C, Shen L, He J, Ye X, Cao W, Wang H, Han W (2021) Phase I study of CAR-T cells with PD-1 and TCR disruption in mesothelin-positive solid tumors. Cell Mol Immunol 18(9): 2188−2198 doi: 10.1038/s41423-021-00749-x

Whilding LM, Halim L, Draper B, Parente-Pereira AC, Zabinski T, Davies DM, Maher J (2019) CAR T-cells targeting the integrin alphavbeta6 and co-expressing the chemokine receptor CXCR2 demonstrate enhanced homing and efficacy against several solid malignancies. Cancers (Basel) 11(5): 674. https://doi.org/10.3390/cancers11050674

Xia L, Zheng Z, Liu JY, Chen YJ, Ding J, Hu GS, Hu YH, Liu S, Luo WX, Xia NS, Liu W (2021) Targeting triple-negative breast cancer with combination therapy of EGFR CAR T cells and CDK7 inhibition. Cancer Immunol Res 9(6): 707−722 doi: 10.1158/2326-6066.CIR-20-0405

Yang M, Tang X, Zhang Z, Gu L, Wei H, Zhao S, Zhong K, Mu M, Huang C, Jiang C, Xu J, Guo G, Zhou L, Tong A (2020a) Tandem CAR-T cells targeting CD70 and B7-H3 exhibit potent preclinical activity against multiple solid tumors. Theranostics 10(17): 7622−7634 doi: 10.7150/thno.43991

Yang P, Wang Y, Yao Z, Gao X, Liu C, Wang X, Wu H, Ding X, Hu J, Lin B, Li Q, Li M, Li X, Chen X, Qi W, Li W, Xue J, Xu H (2020b) Enhanced safety and antitumor efficacy of switchable dual chimeric antigen receptor-engineered T cells against solid tumors through a synthetic bifunctional PD-L1-blocking peptide. J Am Chem Soc 142(44): 18874−18885 doi: 10.1021/jacs.0c08538

You F, Jiang L, Zhang B, Lu Q, Zhou Q, Liao X, Wu H, Du K, Zhu Y, Meng H, Gong Z, Zong Y, Huang L, Lu M, Tang J, Li Y, Zhai X, Wang X, Ye S, Chen D, Yuan L, Qi L, Yang L (2016) Phase 1 clinical trial demonstrated that MUC1 positive metastatic seminal vesicle cancer can be effectively eradicated by modified anti-MUC1 chimeric antigen receptor transduced T cells. Sci China Life Sci 59(4): 386−397 doi: 10.1007/s11427-016-5024-7

Zhang J, Hu Y, Yang J, Li W, Zhang M, Wang Q, Zhang L, Wei G, Tian Y, Zhao K, Chen A, Tan B, Cui J, Li D, Li Y, Qi Y, Wang D, Wu Y, Li D, Du B, Liu M, Huang H (2022a) Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL. Nature 609(7926): 369−374 doi: 10.1038/s41586-022-05140-y

Zhang X, Wang T, Zhu X, Lu Y, Li M, Huang Z, Han D, Zhang L, Wu Y, Li L, Klawonn F, Stripecke R (2023) GMP development and preclinical validation of CAR-T cells targeting a lytic EBV antigen for therapy of EBV-associated malignancies. Front Immunol 14: 1103695. https://doi.org/10.3389/fimmu.2023.1103695

Zhang X, Zhang C, Qiao M, Cheng C, Tang N, Lu S, Sun W, Xu B, Cao Y, Wei X, Wang Y, Han W, Wang H (2022b) Depletion of BATF in CAR-T cells enhances antitumor activity by inducing resistance against exhaustion and formation of central memory cells. Cancer Cell 40(11): 1407‒1422 e1407

Zhang Z, Jiang D, Yang H, He Z, Liu X, Qin W, Li L, Wang C, Li Y, Li H, Xu H, Jin H, Qian Q (2019) Modified CAR T cells targeting membrane-proximal epitope of mesothelin enhances the antitumor function against large solid tumor. Cell Death Dis 10(7): 476. https://doi.org/10.1038/s41419-019-1711-1

Zhao R, Cui Y, Zheng Y, Li S, Lv J, Wu Q, Long Y, Wang S, Yao Y, Wei W, Yang J, Wang BC, Zhang Z, Zeng H, Li Y, Li P (2021) Human hyaluronidase PH20 potentiates the antitumor activities of mesothelin-specific CAR-T cells against gastric cancer. Front Immunol 12: 660488. https://doi.org/10.3389/fimmu.2021.660488

Zhou M, Chen M, Shi B, Di S, Sun R, Jiang H, Li Z (2022) Radiation enhances the efficacy of EGFR-targeted CAR-T cells against triple-negative breast cancer by activating NF-kappaB/Icam1 signaling. Mol Ther 30(11): 3379−3393 doi: 10.1016/j.ymthe.2022.07.021

Zou F, Tan J, Liu T, Liu B, Tang Y, Zhang H, Li J (2021) The CD39(+) HBV surface protein-targeted CAR-T and personalized tumor-reactive CD8(+) T cells exhibit potent anti-HCC activity. Mol Ther 29(5):1794−1807

Supplements(1)